Jacob Kimmel is the co-founder and CEO of NewLimit. At NewLimit, he is involved in developing therapeutics, focusing on the intersection of "atoms and bits." Prior to co-founding NewLimit, Kimmel worked at Calico Life Sciences. He also gained experience as a Deep Learning Research Intern at IBM, where his work focused on cell engineering.